Physician profile
Eric J Feldman
NPI 1972690055
$4,911.67
in general payments reported to CMS, 2019-2025
10 companies · $4,422 in 2025
The $4,422 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.91 · 2023: $274 · 2024: $187 · 2025: $4,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,375 · Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,375.00 |
| Food and Beverage | $507.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,375.00 | 2025 | |
| Cti Biopharma Corp. | $214.07 | 2023 | Vonjo |
| Jazz Pharmaceuticals INC. | $123.12 | 2024 | |
| Incyte Corporation | $66.93 | 2022-2023 | Jakafi |
| Abbvie INC. | $46.33 | 2024-2025 | |
| Celgene Corporation | $23.19 | 2024 | |
| Deciphera Pharmaceuticals INC. | $21.58 | 2024 | Qinlock |
| Stemline Therapeutics INC. | $21.49 | 2023 | Orserdu |
| Janssen Biotech, INC. | $19.96 | 2025 | Darzalex, Tecvayli, Talvey |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.